Galcanezumab recommended for migraine prevention in final NICE guidance
Clinical trial evidence shows it works better than best supportive care in both episodic and chronic migraine.
Published
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date
